2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2010

Anti-Endothelial Cell Antibodies in Pediatric Rheumatic Diseases
Abstract Number: 2011

Juvenile Arthritis-Associated Single Nucleotide Polymorphisms Identified on Whole Genome Sequencing Show Enrichment within H3K9me3-Marked Regions
Abstract Number: 2012

The Novel G58V Mutation in the TNFRSF1A Gene Identified in a Family with Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS) Decreases the Cell Surface Expression of TNFR1
Abstract Number: 2014

Next Generation Sequencing Analysis of Familial Haemophagocytic Lymphohistiocytosis (HLH) Related Genes in Macrophage Activation Syndrome (MAS) and Secondary HLH (sHLH)
Abstract Number: 2015

Association of Anti-Ro52 Autoantibodies with Interstitial Lung Disease and More Severe Disease Manifestations in Juvenile Idiopathic Inflammatory Myopathies
Abstract Number: 2016

The Chromatin Landscape Around the Juvenile Arthritis-Associated CXCR4 Locus Suggests Regulatory Functions and Genetic Roles in Both Innate and Adaptive Immunity
Abstract Number: 2017

Oral Microbiota in New-Onset Juvenile Idiopathic Arthritis
Abstract Number: 2018

Microenvironment Driven Re-Shaping of Pathogenic T Effector and Regulatory Subset in Active Juvenile Idiopathic Arthritic Patients
Abstract Number: 2019

Investigating Urine S100A4 and Podocyte Proteins As Biomarkers of Lupus Nephritis Activity
Abstract Number: 2020

Novel Serum Biomarkers Monitor Disease Progression and Response to Change in Corticosteroid Therapy in Children with Juvenile Dermatomyositis
Abstract Number: 2021

Th22 Cells in Peripheral Blood and Synovial Fluid of Patients with Enthesitis Related Arthritis
Abstract Number: 2022

Evidence of Inflammation Amplification By Interleukin-6 and Interleukin-17A in Synovial Compartment of Juvenile Idiopathic Arthritis – Enthesitis Related Arthritis
Abstract Number: 2023

Different Patterns of Interferon-Response-Gene Expression May Elucidate Different Pathomechanisms That Drive IFN-Response-Gene Activation in Patients with Presumed IFN-Mediated Autoinflammatory Diseases
Abstract Number: 2024

Comparison of B and T Cell Subsets, Cytokine Expression and Synovial Pathology in Down’s Arthritis (DA) and Juvenile Idiopathic Arthritis (JIA)
Abstract Number: 2025

Fibroblast-like Synoviocytes from Juvenile Idiopathic Arthritis and Controls Influence Expression of Bone Morphogenetic Protein Antagonists in Chondrocytes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].